Business Description
Dyne Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US26818M1080
Share Class Description:
DYN: Ordinary SharesTotal Employee Number:
258Description
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.76 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | -0.38 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -1.5 | |||||
3-Year EPS without NRI Growth Rate | -2.4 | |||||
3-Year FCF Growth Rate | -3.1 | |||||
3-Year Book Growth Rate | 9.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.84 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 82.83 | |||||
9-Day RSI | 76.52 | |||||
14-Day RSI | 70.74 | |||||
3-1 Month Momentum % | -8.49 | |||||
6-1 Month Momentum % | -6.81 | |||||
12-1 Month Momentum % | 92.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 19.92 | |||||
Quick Ratio | 19.92 | |||||
Cash Ratio | 18.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -43.7 | |||||
Shareholder Yield % | -18.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -59.92 | |||||
ROA % | -49.27 | |||||
ROIC % | -859.31 | |||||
3-Year ROIIC % | -1484.25 | |||||
ROC (Joel Greenblatt) % | -1133.24 | |||||
ROCE % | -50.76 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.41 | |||||
Price-to-Tangible-Book | 4.41 | |||||
EV-to-EBIT | -6.84 | |||||
EV-to-EBITDA | -6.87 | |||||
EV-to-Forward-Revenue | 41.15 | |||||
EV-to-FCF | -6.53 | |||||
| Price-to-Net-Current-Asset-Value | 4.74 | |||||
| Price-to-Net-Cash | 5.05 | |||||
Earnings Yield (Greenblatt) % | -14.62 | |||||
FCF Yield % | -12.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DYN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dyne Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.22 | ||
| Beta | 2.1974 | ||
| 3-Year Sharpe Ratio | 0.48 | ||
| 3-Year Sortino Ratio | 0.95 | ||
| Volatility % | 89.93 | ||
| 14-Day RSI | 70.74 | ||
| 14-Day ATR ($) | 1.155052 | ||
| 20-Day SMA ($) | 19.5565 | ||
| 12-1 Month Momentum % | 92.84 | ||
| 52-Week Range ($) | 8.06 - 25 | ||
| Shares Outstanding (Mil) | 165.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dyne Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dyne Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-07-28 | In 24 days | ||
| Guidance call for 2026 | 2026-06-09 | 16.81 (-2.72%) | ||
| General meeting for 2026 | 2026-06-05 11:00 | 18.41 (+1.43%) | ||
| Guidance call for 2026 | 2026-06-03 09:55 | 17.24 (-5.79%) | ||
| RBC Capital Markets Global Healthcare Conference | 2026-05-20 11:00 | 15.92 (-3.40%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 17.61 (+0.74%) | ||
| Guidance call for 2026 | 2026-03-17 16:00 | 18.13 (-1.31%) | ||
| TD Cowen 46 Annual Health Care Conference | 2026-03-04 11:50 | 14.60 (-5.75%) | ||
| Annual report for 2025 | 2026-03-02 | 15.62 (-0.64%) |
Show
Entries
Dyne Therapeutics Inc Frequently Asked Questions
What is Dyne Therapeutics Inc(DYN)'s stock price today?
The current price of DYN is $23.11. The 52 week high of DYN is $25.00 and 52 week low is $8.06.
When is next earnings date of Dyne Therapeutics Inc(DYN)?
The next earnings date of Dyne Therapeutics Inc(DYN) is 2026-07-28 Est..
Does Dyne Therapeutics Inc(DYN) pay dividends? If so, how much?
Dyne Therapeutics Inc(DYN) does not pay dividend.
Guru Commentaries on NAS:DYN
No articles.
Press Release
Articles on Dyne Therapeutics Inc
No articles.
Headlines
See More- 1
Jun 17, 2026
Dyne Therapeutics expands debt facility with Hercules Capital to $400M
Seeking Alpha • 6:53am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers